CPT code 96405 denotes intralesional chemotherapy administration to one through seven lesions or tumors and is used to bill for localized chemotherapeutic treatment delivered directly into tumor sites. This code matters nationally because it captures a targeted oncologic procedure that may be performed in multiple ambulatory settings and can affect site-of-service payment differentials, utilization monitoring, and coverage policy development for localized cancer therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for intralesional chemotherapy, expected service settings, common modifiers and billing considerations, and national benchmarking and policy implications where available. The publication outlines how payers commonly handle coverage determinations and documentation expectations for lesion-based chemotherapy procedures.

This resource summarizes actionable billing and coding context, clarifies when CPT code 96405 applies, and highlights areas where payers and providers often focus review efforts. Data not available in the input is noted where applicable, and the piece is intended as a concise national reference for coding, reimbursement discussion, and clinical documentation alignment related to intralesional chemotherapy for one to seven lesions.